Case Report

A Rare De Novo Myoepithelial Carcinoma Ex Pleomorphic Adenoma in a Young Woman

Geeta Ahuja1, Delaram J. Taghipour2, Olubode A. Olufajo1, Bonnie C. Davis3, Babak Shokrani4, and William R. Bond Jr.5

1Clive O. Callender Howard-Harvard Clinical Sciences Outcomes Research Center, Department of Surgery, Howard University College of Medicine, Washington, DC, USA
2Johns Hopkins Bloomberg School of Public Health and Carey Business School, Baltimore, MD, USA
3Department of Radiology, Howard University College of Medicine, Washington, DC, USA
4Department of Pathology, Howard University College of Medicine, Washington, DC, USA
5Division of Otolaryngology/Head & Neck Surgery, Howard University College of Medicine, Washington, DC, USA

Correspondence should be addressed to William R. Bond Jr.; wrbondjr@gmail.com

Received 19 November 2019; Accepted 10 December 2019; Published 26 February 2020

Academic Editor: Yuh Baba

Copyright © 2020 Geeta Ahuja et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Carcinoma ex pleomorphic adenoma, an uncommon neoplasm of the parotid gland, accounts for less than 4% of salivary gland tumors. It arises from a benign pleomorphic adenoma presenting in the sixth to eighth decades of life. We present this as a unique account of a primary parotid gland carcinoma, arising from myoepithelial cells, without a known precursor lesion, in a 28-year-old woman. This presentation seeks to provide familiarity of an unusual presentation of an unexpected rare pathology in a young female patient and the tools utilized for an accurate diagnosis.

1. Introduction

Carcinoma ex pleomorphic adenoma (CXPA) is a malignant transformation that can occur in a benign pleomorphic adenoma and usually accounts for 3.6–4% of all salivary tumors and 5–15% of salivary malignancies [1–5]. CXPA typically arises in the sixth to eighth decades of life and seldom occurs in young adults [6]. The late onset is thought to be secondary to the protracted transformation into malignancy that could take an average of 20 years and up to 50 years [3]. The rate of malignant conversion is 1.5% for the first year and up to 9.5% if left untreated in 15 years [3].

Patients suffering from CXPA tend to have a poor prognosis [7]. The prognosis greatly depends on the pathological staging of CXPA; different factors, such as the extent of invasion, lymph node involvement, and metastasis location, can greatly impact the prognosis of each individual patient [1, 8]. There are various approaches to the management of CXPA particularly when the presentation is unusual.

We present a rare case of CXPA without a known precursor lesion in a 28-year-old female who went on to have a favorable treatment outcome. Written consent was obtained from the patient to publish information and images.

2. Case Report

A 28-year-old woman presented with an expanding painful left-sided soft tissue swelling of the face. The mass was present for only a few months and without any associated facial nerve palsy. Examination revealed a round, well-circumscribed mass in the region of the parotid gland without overlying erythema, edema, or skin breakdown. Intraoral examination showed intact mucosa without evidence of invasion or erosion. CT scan images revealed a heterogeneous mass of the left parotid gland measuring approximately 4.0 × 2.7 × 3.9 cm with hypodense foci suggesting necrosis (Figure 1). A nonspecific level II lymph node was also visualized. Figure 2 displays the ultrasound images of the mass.
Fine needle aspiration and biopsy performed were consistent with a pleomorphic adenoma. At that point, the decision was made to perform a left-sided parotidectomy with intraoperative facial nerve monitoring. The Blair incision (Figure 3) was utilized to help with a deep lobe dissection. The procedure revealed a mass extending to the deep parotid lobe. Careful attention was taken to preserve all branches of the facial nerve, and the mass was surgically excised (Figure 4).

Histological findings displayed an intermediate grade myoepithelial carcinoma arising from a pleomorphic adenoma (Figures 5 and 6). The carcinoma showed greater than 1.5 mm invasion into the surrounding adipose tissue (invasive type) with positive tumor-inked margins. The parotid lymph node did not show any evidence of malignancy. A pathological diagnosis of myoepithelial carcinoma ex pleomorphic adenoma was made. The patient successfully underwent adjuvant radiation therapy with a goal of 60 Gy.

Postoperatively, she experienced transient grade II House–Brackmann facial nerve dysfunction that completely resolved over the next few weeks. To date, she is asymptomatic and disease-free.

3. Discussion

CXPA is infrequent with a prevalence rate of 5.6 cases per 100,000 malignant neoplasms and an incidence by year of 0.17 tumors per 1 million people [1]. It occurs more commonly in females than in males and typically arises around the age of sixty to eighty [1]. The patient presented is a young female at the age of 28, who represents a rare group being treated for this disease. Typically, the mean lead up time for CXPA has been found to be nine years, with about half of the patients aware of a painless mass for below one year [6, 9]. In contrast, the CXPA in this case presented de novo and with clinical symptoms of a painful rapidly enlarging mass over a
period of months, not years. Also, among a retrospective
study that analyzed 151 cases of CXPA, most cases were
frankly invasive high-grade malignancies [5]. Histological
findings in this patient exhibited a lower grade (interme-
diate) myoepithelial carcinoma, again contrasting the typical
findings of CXPA. The combination of all these features
makes this an exceptional case worthy of reporting.

Several epidemiological variations in the presentation of
CXPA have been observed. For example, in Switzerland,
CXPA was found to make up 14% of all primary parotid
malignant neoplasms over 20 years [10]. In the United
States, the reported prevalence was 12% of all primary pa-
rotid malignant neoplasms [11]. In terms of the racial
distribution of CXPA in the United States, the incidence data

Figure 3: Intraoperative dissection using the Blair s-shaped incision with nerve preservation.

Figure 4: A tan/pink firm nodular mass (a, b); with areas of necrosis, hemorrhage, and cystic changes (arrows) (b, c) with attached portion of unremarkable salivary gland (d).
Figure 5: Low power microscopic sections show areas of typical pleomorphic adenoma with chondromyxoid matrix (H&E, ×40) (a), transitioning to the areas composed of cellular nests of atypical cells (arrows) (H&E, ×100) (b) with infiltration and seeding of the surrounding adipose tissue (arrows) (H&E, ×40) (c, d).

Figure 6: High power microscopic sections show atypical myoepithelial cells with increased mitotic activity (arrows) (3D, H&E, ×1000), hyalinized stroma (3C, H&E, ×400) and necrosis (arrows) (3B, H&E, ×200).
shows a rate of 0.77 persons per million in Blacks, 0.71 persons per million in Whites, and 0.34 persons per million among other races [12].

The exact etiology for transformation to CXPA is not well understood. Various studies suggest radiation, genetic instability within the tumor, and increased expression of the cytoplasm of p16 protein by promotor methylation of the p16 gene may all contribute [13, 14]. A molecular study suggests a multistep model with the progressive loss of heterozygosity at chromosomal arms 8q, then 12q, and finally 17p [2, 15]. Genes involved in tumor suppression, cell cycle control, growth, etc., are also involved in the development of CXPA [7]. For example, the p53 gene has been associated with the development of malignant CXPA; point mutation of p53 was reported originally by Righi et al. [16]. Righi et al. found positive expression of the p53 protein and mutation of p53 in four instances of CXPA [16]. Additionally, CXPA cases can be divided into those with only epithelial (luminal) malignancy and those with myoepithelial (nonluminal) malignancy [7]. Myoepithelial cells have been shown to provide fuel for tumor progression [17]. It is hoped that these markers could be used to provide helpful hints in the future diagnosis and management of CXPA and lead to a better prognosis for affected patients [7].

CXPA normally presents as a firm mass on the parotid gland [7]. Patients may only become aware of the tumor when they notice rapid enlargement and pain and are otherwise asymptomatic [6]. A patient diagnosed with noninvasive or minimally invasive CXPA has a much better prognosis than a patient with invasive CXPA diagnosis [8]. The tumor size and grade are also important factors in determining the prognosis [8]. Besides all these factors, early accurate diagnosis and appropriate surgical and radiological management of CXPA are essential in improving the outcome of this disease [8].

Preoperative diagnosis of CXPA can be challenging for clinicians and pathologists [7]. When there is a high clinical or radiological suspicion, pathological confirmation is sought [7]. Fine needle aspiration is frequently used to diagnose CXPA, although its sensitivity is relatively low [7]. An earlier study in 1999 showed a relatively high rate of sensitivity, in which 54% of patients with CXPA were diagnosed before operation with fine needle sampling [18]. However, in a recent study conducted in 2008, 44% of CXPA cases were found to be malignant by fine needle aspiration, and a 2005 study found the number to be even lower, at only 29% [10, 19]. When used alone, the preoperative diagnostic methods available for CXPA lack veracity. Therefore, a combination of diagnostic tools including radiological and pathological tests is required in order to best make an accurate preoperative diagnosis [20].

The definitive treatment for CXPA usually involves ablative surgery, which may be followed with reconstructive surgery [6, 19]. The specific surgical approach varies depending on the site of the CXPA. Because CXPA tends to affect the parotid gland, surgery typically involves parotidectomy [6, 19]. For CXPA in the lacrimal gland, lateral rhinotomy and medial maxillectomy is recommended [21]. Tracheal CXPA requires a segmental tracheal resection and a suprathyroid release [22]. For high-grade disease, indeterminate resection adequacy and lymph node and perineural invasion, adjuvant radiotherapy is usually employed [9]. Combination of radiotherapy and chemotherapy is used in selected cases [9, 19].

The reported 5-year survival of CXPA has been found to vary. A 5-year survival rate of 37% among 73 patients and 44% among 28 patients was found among studies conducted in 2001 and 2005, respectively [6, 19]. Another study by Zbaren et al. found the 5-year survival rate to be much higher, at 75% among 24 patients [10]. This higher survival rate could be due to the greater amount of intracapsular CXPA in the study since intracapsular CXPA can act similar to a benign pleomorphic adenoma and have a better prognosis [9].

4. Conclusion

CXPA remains a rare disease that is difficult to diagnose both clinically and pathologically. Because of the significant clinical implications associated with the late diagnosis of the disease, the ongoing efforts to identify better diagnostic modalities are critical. This rare case of CXPA presented is thus vital to furthering the current understanding of the condition, as it represents a novel presentation and can serve as an exemplar for future diagnoses. Further research and investigation on CXPA are needed to help lead to earlier diagnoses and treatments for patients.

Consent

Written informed consent was obtained for the patient information and images.

Disclosure

This case report was presented at the American Academy of Otolaryngology-Head and Neck Surgery Foundation 2016 Annual Meeting and OTO EXPO; San Diego, California; September 2016.

Conflicts of Interest

The authors declare that there are no relevant conflicts of interest.

References

[1] D. R. Gnepp, “Malignant mixed tumors of the salivary glands: a review,” *Pathology Annual*, vol. 28, no. 1, p. 328, 1993.
[2] V. A. LiVolsi and K. H. Perzin, “Malignant mixed tumors arising in salivary glands. I. Carcinomas arising in benign mixed tumors: a clinicopathologic study,” *Cancer*, vol. 39, no. 5, pp. 2209–2230, 1977.
[3] R. H. Spiro, A. G. Huvos, and E. W. Strong, “Malignant mixed tumor of salivary origin. A clinicopathologic study of 146 cases,” *Cancer*, vol. 39, no. 2, pp. 388–396, 1977.
[4] F. W. Foote Jr. and E. L. Frazell, “Tumors of the major salivary glands,” *Cancer*, vol. 6, no. 1, 1953.
[5] P. Ye, Y. Gao, C. Mo, C. B. Guo, G. Y. Yu, and X. Peng, “Carcinoma ex pleomorphic adenoma: is it a high grade
malignancy?” *Journal of Oral and Maxillofacial Surgery*, vol. 74, no. 10, pp. 2093–2104, 2016.

[6] K. D. Olsen and J. E. Lewis, “Carcinoma ex pleomorphic adenoma: a clinicopathologic review,” *Head & Neck*, vol. 23, no. 9, pp. 705–712, 2001.

[7] J. Antony, V. Gopalan, R. A. Smith, and A. K. Y. Lam, “Carcinoma ex pleomorphic adenoma: a comprehensive review of clinical, pathological and molecular data,” *Head and Neck Pathology*, vol. 6, no. 1, pp. 1–9, 2012.

[8] L. Barnes, J. W. Eveson, P. Reichart, and D. Sidransky, *World Health Organisation Classification of Tumours: Pathology and Genetics of Head and Neck Tumours*, IARC Press, Lyon, France, 2015.

[9] J.-C. Lüers, C. Wittekindt, M. Streppel, and O. Guntinas-Lichius, “Carcinoma ex pleomorphic adenoma of the parotid gland. Study and implications for diagnostics and therapy,” *Acta Oncologica*, vol. 48, no. 1, pp. 132–136, 2009.

[10] P. Zbären, S. Zbären, M. D. Caversaccio, and E. Stauffer, “Carcinoma ex pleomorphic adenoma: diagnostic difficulty and outcome,” *Otolaryngology-Head and Neck Surgery*, vol. 138, no. 5, pp. 601–605, 2008.

[11] M. N. Byrne and J. G. Spector, “Parotid masses: evaluation, analysis, and current management,” *Laryngoscope*, vol. 98, no. 1, pp. 99–105, 1988.

[12] C. Rebun and R. O. Wein, “The incidence of salivary carcinoma ex pleomorphic adenoma,” *SEER Database*, vol. 5, no. 1, 2015.

[13] Y. H. Hu, C. Y. Zhang, Z. Tian, L. Z. Wang, and J. Li, “Aberrant protein expression and promoter methylation of p16 gene are correlated with malignant transformation of salivary pleomorphic adenoma,” *Archives of Pathology & Laboratory Medicine*, vol. 135, no. 7, pp. 882–889, 2011.

[14] C. M. Eneroth and A. Zetterberg, “Malignancy in pleomorphic adenoma. A clinical and microspectrophotometric study,” *Acta Oto-Laryngologica*, vol. 77, no. 6, pp. 426–432, 1974.

[15] A. K. El-Naggar, D. Callender, and M. M. Coombs, “Molecular genetic alterations in carcinoma ex-pleomorphic adenoma: a putative progression model?” *Genes Chromosomes Cancer*, vol. 27, no. 2, 2000.

[16] P. D. Righi, Y. Q. Li, M. Deutsch, and J. S. McDonald, “The role of the p53 gene in the malignant transformation of pleomorphic adenomas of the parotid gland,” *Anticancer Research*, vol. 14, no. 5B, pp. 2253–2257, 1994.

[17] E. F. Martinez, N. S. de Araujo, and V. C. de Araujo, “How do benign myoepithelial cells from in situ areas of carcinoma ex-pleomorphic adenoma favor tumor progression?” *Journal of Cell Communication and Signaling*, vol. 9, no. 3, pp. 279-280, 2015.

[18] J. Klijanienko, A. K. El-Naggar, and P. Vielh, “Fine-needle sampling findings in 26 carcinoma ex pleomorphic adenomas: diagnostic pitfalls and clinical considerations,” *Diagnostic Cytopathology*, vol. 21, no. 2, 1999.

[19] S. A. R. Nouraei, K. L. Hope, C. G. Kelly, N. R. McLean, and J. V. Soames, “Carcinoma ex benign pleomorphic adenoma of the parotid gland,” *Plastic and Reconstructive Surgery*, vol. 116, no. 5, pp. 1206–1213, 2005.

[20] C. Raine, K. Saliba, A. J. Chippindale, and N. R. Mclean, “Radiological imaging in primary parotid malignancy,” *British Journal of Plastic Surgery*, vol. 56, no. 7, pp. 637–643, 2003.

[21] S. Baredes, D. B. Ludwin, Y. L. Troublefield, P. D. Langer, and N. Mirani, “Adenocarcinoma ex-pleomorphic adenoma of the lacrimal sac and nasolacrimal duct: a case report,” *The Laryngoscope*, vol. 113, no. 6, pp. 940–942, 2003.

[22] C. S. L. Ding, W. M. Yap, C. H. Y. Teo, D. Giron, and K. L. Chuah, “Tracheal carcinoma ex pleomorphic adenoma: a rare tumour with potential problems in diagnosis,” *Histopathology*, vol. 51, no. 6, pp. 868–871, 2007.